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Abstract
This article contributes to the development of methods for analysing research funding sys-
tems by exploring the robustness and comparability of emerging approaches to generate
funding landscapes useful for policy making. We use a novel dataset of manually extracted
and coded data on the funding acknowledgements of 7,510 publications representing UK can-
cer research in the year 2011 and compare these ‘reference data’ with funding data provided
by Web of Science (WoS) and MEDLINE/PubMed. Findings show high recall (about 93%)
of WoS funding data. By contrast, MEDLINE/PubMed data retrieved less than half of the
UK cancer publications acknowledging at least one funder. Conversely, both databases have
high precision (+90%): i.e. few cases of publications with no acknowledgement to funders
are identified as having funding data. Nonetheless, funders acknowledged in UK cancer pub-
lications were not correctly listed by MEDLINE/PubMed and WoS in about 75% and 32%
of the cases, respectively. ‘Reference data’ on the UK cancer research funding system are
then used as a case-study to demonstrate the utility of funding data for strategic intelligence
applications (e.g. mapping of funding landscape, comparison of funders’ research portfolios).
Keywords: funding data; acknowledgments; precision; recall ; bibliometrics; scientomet-
rics; cancer research; MEDLINE/PubMed; ISI Web of Science.
∗n.grassano@sussex.ac.uk
†Corresponding author: d.rotolo@sussex.ac.uk, @danielerotolo, Phone: +44 1273 872980
‡j.r.hutton@sussex.ac.uk
§f.lang@sussex.ac.uk
¶m.mhopkins@sussex.ac.uk
‖DOI: 10.1002/jasist.23737. c©2016 Grassano, et al. Distributed under CC-BY-NC-ND.
1
ar
X
iv
:1
60
4.
04
89
6v
1 
 [c
s.D
L]
  1
7 A
pr
 20
16
1 Introduction
In the present climate of fiscal austerity, research funding is falling in a number of countries
(BIS, 2015). Questions about the efficiency of funding mechanisms are therefore very much
in the minds of policy makers and science policy analysts. Some advocate closer monitoring
and measurement to optimise the ‘yield’ from research (Chalmers et al., 2014). Others suggest
funders should consider the types of research they support, ensuring they maintain diversity
(Wallace and Rafols, 2015). In this context, understanding the relationship between funding
inputs and research outputs has important implications for the design and management of re-
search at the level of grants, programmes, agencies’ portfolios, and even at the national and
international funding landscape level (e.g. where interdependencies and complementarities be-
tween funders could be identified, and co-ordination can improve efforts to address particular
diseases).
Funders are investing in the development of data infrastructures capable of supporting such
efforts as well as of increasing the transparency around funding decisions. These include the
RePORTER database of the US National Institutes for Health (NIH), the Gateway to Research
of the Research Councils UK (RCUK), and the OpenAIRE of the European Commission. Some
funders have also combined efforts in order to compare their research portfolios and to track
national trends in funding (UKCRC, 2014). However, considering the diversity of funders that
populate funding systems, these efforts, led by major funders, do not include data on the activ-
ities of numerous smaller organisations that also support research.
In order to consider the research being funded in a given field or country and to reflect on
changes to funding policies, it is desirable to obtain a comprehensive overview of the funding
landscape by tracing inputs and outputs from a wide range of funders and researchers that are
active in a given area. One promising source of data for this purpose is the information included
in the acknowledgement paratext of scientific publications where authors commonly give thanks
for support (e.g. Costas and van Leeuwen, 2012; Dawson et al., 1998; Rigby, 2011). In particular,
funding information in acknowledgements has the potential to establish a direct link between
funding inputs and research outputs on a grand scale, without the need to gain direct access
to data via individual funders or researchers. This paper explores a number of approaches to
using funding data derived from in publication acknowledgements. In doing so, we address key
questions about the coverage of these data and explore the utility of mapping funding landscapes
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using these data.
Making systematic use of the funding information included in the acknowledgment sections
of publications is, however, difficult due to the lack of standardization in the structure and
content of acknowledgements — in contrast to references, for example. In order to support the
use of acknowledgement paratext some databases, such as ISI Web of Science (WoS) and MED-
LINE/PubMed, provide ready-extracted and coded funding data. Yet, uncertainties remain
about the coverage of such sources (Koier and Horlings, 2014; Rigby, 2011). The motivation for
this paper is to resolve some of the uncertainties of working with funding data, in the hope that
improving methods and resources for the use of these data can help to improve research policy.
Our analysis focuses on 7,510 publications in cancer research published in the year 2011 and
involving at least one author affiliated with a UK research host organisation (see Shah et al.,
2014). Cancer represents by far the largest single disease area studied in the UK, attracting an
estimated 20% of funding invested by the government and major research charities (UKCRC,
2014). For each publication in the sample, we extracted and coded funding data from the
acknowledgment sections and used these data for three purposes: (i) to devise heuristics that
can provide grounds for future systematic collection of funding data from acknowledgements;
(ii) to provide one of the first assessments, in terms of recall and precision, of the coverage of
funding data available from MEDLINE/PubMed and WoS; (iii) to illustrate how bibliometric
analysis of funding data taken from acknowledgment sections can be used to generate intelligence
on funding systems to inform policy making in terms of most active funders, co-funding (i.e.
joint occurrence of funders in publication acknowledgements), and funders’ portfolio profiles of
funded research.
The paper proceeds as follows: The next section positions the contribution of the present
paper within the growing bibliometric literature on the use of acknowledgment sections of sci-
entific publications; we then describe the methodological approach used to collect and code the
data and introduce a number of procedural points of guidance on how to recognise and isolate
funding information in the acknowledgment sections, as well as on how to codify this informa-
tion; in the Results section, we examine the extent to which authors acknowledge funders in
their publications; we compare, in terms of precision and recall, our data with those extracted
by queries of the same set of publications from MEDLINE/PubMed and WoS; we then use the
data to illustrate applications in funding portfolio and landscape analysis; we conclude the paper
by discussing the main results of the approach we propose as well as the caveats and limitations
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associated with it.
2 Literature review and emerging questions
The breadth of information on scientific research activity that is included in the acknowledgment
paratext of scientific publications has attracted the attention of bibliometric researchers since
the 1970s. Pioneering work by Mackintosh (1972), Cronin (1991), and McCain (1991) focused
on taxonomising the information contained in these sections. Mackintosh (1972), for example,
analysed the scientific articles published in the American Sociological Review from 1940 to 1962
and defined three types of acknowledgments, i.e. facilities, access to data, and help of individuals.
Cronin’s (1991) taxonomy specifically included: (i) paymasters (i.e. funding), (ii) moral support
(e.g. use of equipment, access to data), (iii) dogsbody (e.g. secretarial support, editorial guidance,
data collection and analysis), (iv) technical (e.g. access to know-how, guidance on statistical
procurers), (v) prime mover (e.g. inspiration provided by principal investigator, project directors,
mentor), and (vi) trusted assessor (e.g. feedback, critical analysis and comments from peers).
Scholars have subsequently exploited publication acknowledgements for different bibliometric
and evaluation purposes. These include the analysis of patterns of subauthorship or peer inter-
active communication, such as formal or informal assistance and acknowledgments to reviewers
(e.g. Cronin and Franks, 2006; Cronin et al., 1992, 2003, 2004; Tiew and Sen, 2002), as well as
the cataloguing of the funding authors received to produce their publications (e.g. Harter and
Hooten, 1992; Lewison, 1994; Lewison et al., 1995). The latter has received extensive attention
because of the potential for linking research funding inputs with scientific outputs.
A considerable effort in this direction was made by Dawson et al. (1998) with the development
of the Wellcome Trust’s Research Output Database (ROD). The ROD included bibliographic
information of about 214,000 UK biomedical publications between 1988 and 1995 and funding
data extracted from the acknowledgement sections of these publications. This database enabled
researchers to examine, for the first time and on a relatively large scale, the mix of funding
sources in specific biomedical domains (Lewison, 1998) and the extent to which funded and
unfunded publications differ in terms of type of research (Lewison and Devey, 1999) and impact
as measured on the basis of citation-based indicators (Lewison and Dawson, 1998; Lewison
et al., 2001; MacLean et al., 1998). These studies provided seminal evidence, for example, that
publications acknowledging funders are likely to receive more citations than those not reporting
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acknowledgment to funders. Yet, this relationship was also found to be dependent on the
research domain and type of citation-based indicator used (Cronin and Shaw, 1999; Lewison
and Carding, 2003).
These studies provided important insights on the extent to which authors acknowledged their
funders. Table 1 reports a summary of these and subsequent studies. It is worth noting that sub-
stantial variation in funding acknowledgment frequencies exists — varying with research focus,
journal, funder, and country. For example, the ROD database provides an overview of funding
in several biomedical fields, with around 64% of the publications acknowledging funders Dawson
et al. (1998). However, this figure masks considerable variation with publications. For example,
in gastroenterology, arthritis and malaria research funders were acknowledged in about 54%,
60%, and 80% of the cases, respectively (e.g Lewison, 1998; Lewison and Devey, 1999; MacLean
et al., 1998). More recently, Costas and van Leeuwen (2012) found that more than 50% of the
publications in natural sciences (e.g. molecular biology and biochemistry, chemistry, physics and
astronomy, and geosciences) reported funders in their acknowledgments, while publications in
applied/clinical sciences (engineering, clinical medicine), mathematics, social sciences applied
to medicine, psychology, psychiatry, and behavioral sciences reported funders in only 20-50% of
cases. Publications in economics, social sciences, and humanities and arts reported funding in
even fewer cases, typically less than 10%. Similar patterns were found by Dı´az-faes and Bordons
(2014) on a sample of about 40,000 publications published in 2010 by Spanish researchers. On
the one hand these figures highlight differences in the funding required to undertake research
(e.g. between humanities and natural sciences), but on the other hand differences may also reflect
norms of reporting at different times and in different places.
Acknowledgement patterns in journals might be expected to follow the rates of acknowledge-
ments in the field they cover. For example, Zhao (2010) showed that articles published in library
and information science journals (e.g. Journal of the American Society for Information Science,
Information Processing and Management, Journal of Documentation, and College and Research
Libraries) include funding acknowledgements from about 6% to 35% of the cases (see Table 1),
while Rigby’s (2011; 2013) analysis of articles included in Cell revealed much higher funding ac-
knowledgement rates (94%). Great variations were found across journals in social sciences and
humanities, such as psychology, sociology, history, and philosophy Cronin et al. (1993): articles
in Psychological Review, American Sociological Review, American Historical Review, and Mind
acknowledged funders in 70.3%, 53.5%, 29.7%, and 3.0% of the cases, respectively.
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Table 1: Reporting of funding data in publication acknowledgements in terms of journals, research
domains, funders, and countries.
Studies by main Data source Sample % of records reporting
analytical focus (period of observation) funding data
Journal(s)
Cronin (1991) J. of the Am. Soc. for Inf. Science (1970-1990) 938 29.1%
Harter and Hooten (1992) J. of the Am. Soc. for Inf. Science (1972-1974,
1982-1984, 1988-1990)
391 32.2%
Cronin et al. (1993) Sample of journals (1971-1990):
Psychological Review 629 70.3%
Am. Sociological Review 1,186 53.5%
Am. Historical Review 464 29.7%
Mind 1,027 3.0%
Cronin and Shaw (1999) Four information science journals (1989-1993) 716 26.5%
Tiew and Sen (2002) J. of Natural Rubber Research (1986-1997) 310 20.3%
Cronin et al. (2003, 2004) Sample of journals (1900-1990):
Psychological Review 2,707 31.9%
Mind 1,850 3.4%
Cronin and Franks (2006) Cells (1975, 1985, 1995, 2004) 1,106 86.8%-96.6%
Zhao (2010) Sample of journals (1998):
J. of the Am. Soc. for Inf. Science 99 35.4%
Inf. Processing and Management 46 34.8%
J. of Documentation 24 33.3%
Library and Inf. Science Research 17 29.4%
Library Trends 33 12.1%
Library Quarterly 12 16.7%
College and Research Libraries 35 5.7%
Rigby (2011) Sample of journals (-):
Cell 301 94.0%
Physical Review Letters 3,414 83.0%
Rigby (2013) J. of Biological Chemistry (2009) 3,596 89.9%
Research domain(s)
Lewison et al. (1995) Sample of UK biomedical articles (1988-1992) ∼122,000 61.0%
Dawson et al. (1998) Wellcome Trust’s Research Outputs Database
(ROD) (1988-1995)
214,364 63.6%
Lewison (1998); Lewison
and Dawson (1998); Lewi-
son et al. (2001)
Sample of gastroenterology articles (1988-1994) 12,925 54.4%
MacLean et al. (1998) Sample of malaria articles (1989) 758 80.5%
Lewison and Devey (1999) UK articles in arthritis research (1988-1995) 6,672 60.3%
Lewison and Carding
(2003)
Articles in language therapy research (1991-2000) 1,048 51.0%
Giles and Councill (2004) Articles in CiteSeer (1990-2004) 335,000 56.1%
Shapira and Wang (2010);
Wang and Shapira (2011)
Sample of nanotechnology articles (2008-2009) 91,164 66.9%
Costas and van Leeuwen
(2012)
WoS articles (2009) 1,253,909 43.2%
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Table 1: Reporting of funding data in publication acknowledgements in terms of journals, research
domains, funders, and countries(continued).
Studies by main Data source Sample % of records reporting
analytical focus (period of observation) funding data
Funder(s)
Lewison (1994) Sample of articles supported by the EU BAP as
reported by surveyed authors (1986-1992)
584 72.9%
Butler (2001) Articles funded by the Australian NHMRC (1994-
1995)
2,962 75.2%
Koier and Horlings (2014) Articles funded by the Dutch climate programmes
(2009-2012)
221 52.9%
Countries
Salager-Meyer et al. (2009) Sample of medical articles (2005-2007):
Spain 50 4.0%
United States 50 26.0%
Venezuela 50 72.0%
Wang et al. (2012) Articles from 10 countries (2009):
United States 379,321 44.1%
China 126,931 70.3%
Germany 102,927 40.8%
United Kingdom 99,832 42.6%
Japan 87,582 43.0%
France 73,186 38.1%
Italy 62,609 33.1%
Canada 60,723 49.1%
Spain 48,245 51.6%
Australia 18,590 44.9%
Dı´az-faes and Bordons
(2014)
Articles produced by Spanish researchers (2010) 38,257 72.6%
Go¨k et al. (2016) Articles from 6 countries (2008-2011) 242,406 ∼44%
Source: Authors’ elaboration.
Countries with very different funding systems also can be expected to have markedly different
acknowledgment rates. Butler (2001) found that researchers funded by the Australian National
Health and Medical Research Council (NHMRC) acknowledge their funder in 75% of papers.
Costas and van Leeuwen (2012) found that articles authored by Chinese researchers acknowledge
funders in about 65% of cases. Publications authored by researchers in South Korea, Taiwan,
Sweden, Finland, Denmark, Spain, and Canada acknowledged funders in more than 50% of the
publications, while funding was acknowledged in less than 40% of the publications of authors
based in Turkey, Greece, Iran, Poland, India, Italy, and Israel. Similarly, Wang et al. (2012) has
shown in a study of 10 countries that 70% of publications from China, but only 33% of those
from Italy, carry funding acknowledgements.
Beyond variation in the occurrence of funding acknowledgments, the analysis of the rela-
tionship between funding and impact has been a key application of funding data in publication
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acknowledgments. Evidence of the positive correlation between the presence of funding acknowl-
edgments in a publication and the citations the publication received were found by Zhao (2010)
on a sample of articles published in library and information science journals. Boyack and Jordan
(2011) examined over 2.5 million publication records from 1980 to 2009 in MEDLINE/PubMed
and found that publications acknowledging funding from the US Public Health Service (includ-
ing the NIH) were cited twice as much as publications authored by US researchers acknowledging
no funding source. However, as discussed above, the relationship between funding and impact
varies across journals, research domains, and countries. For example, Rigby (2011, 2013) found
that there is a weak positive relationship between the number of acknowledged funding sources
and the citation impact of the publications included in Physical Review Letters and the Journal
of Biological Chemistry and that this relationship becomes statistically non-significant in the
case of publications included in Cell. Furthermore, a recent study by Go¨k et al. (2016) pro-
vides evidence that the variety of the acknowledged funding sources (i.e. the number of distinct
funding sources) is positively related to the total number of citations a publication receives and
to the top percentile citations. Yet, the funding intensity (i.e. the number of unique funders
acknowledged in a publication over the number of authors listed in the publication) was found
to negatively affect citation impact.
With important findings beginning to accumulate from the study of funding acknowledge-
ments, the question arises about the ‘quality’ of the underlying data. Early work on the manual
coding of acknowledgments data pointed towards the difficulty of using these data, attributed
to the lack of structure in unstandardized free-form formats. There are challenges in terms of
finding acknowledgement data in the full-text as well as in extracting funding data from text in a
consistent manner. Acknowledgements are not solely found in specific sections called ‘acknowl-
edgements’. Some journals have separate sections on funding, or include acknowledgements at
the beginning or the end of the documents or even in small print without a section indicator.
Building samples of data has typically relied on intensive manual work both to retrieve publi-
cations, for which the electronic access was not available, and to identify and classify the text
of the acknowledgment sections of these publications (e.g. identification and characterisation of
funders by type and nationality). Only a few attempts were made to develop algorithms capable
of extracting publication acknowledgments and the funding data included in these (e.g. Giles
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and Councill, 2004).1
For this reason, research on the use of acknowledgment funding data for large-scale biblio-
metric analyses was limited until in more recent years a new wave of studies has emerged with
much higher sample sizes (e.g. Costas and van Leeuwen, 2012; Dı´az-faes and Bordons, 2014;
Go¨k et al., 2016; Shapira and Wang, 2010). These studies have mostly been facilitated by the
increasing availability of ready-classified information. WoS, for example, has recently provided
access to the funding text of acknowledgments and to the list of funders and grant codes men-
tioned in these — this information is reported in the “FX” and “FU” fields, respectively — for
publications from August 2008.
Nonetheless, we have limited knowledge on the recall and precision of acknowledgement
funding data gathered through automated routines and provided by publication databases such
as MEDLINE/PubMed and WoS. For example, on a sample of 117 publications supported by
“Dutch climate programmes”, Koier and Horlings (2014) found that WoS did not correctly
report the list of funders in about 51% of the cases. This therefore raises questions of the extent
to which these limitations of WoS funding data also occurs in other domains and on how much
additional benefit remains to be gained from manual coding of funding data in acknowledgments
as compared to relying on data from major databases. A second problem that emerges when
working with acknowledgement data concerns the standardisation and disambiguation of funders’
names. Algorithms can support this process, yet ambiguity remains with regard to the selection
of the level of analysis and on the treatment of funders that have changed their names over time
(Rigby, 2011).
This paper aims to address some of these concerns and to contribute to the extant literature
in three ways. Firstly, we develop a series of ‘heuristics’ to guide the collection and coding of
acknowledgment funding data, and provide some cautionary advice on their use. This feeds into
ongoing debates over a greater standardisation of acknowledgment sections, which can facilitate
guidelines for authors of publications, and for analysts extracting and coding of information
there included. Secondly, we examine the recall and precision of MEDLINE/PubMed and WoS
in retrieving publications that reported acknowledgements to funders as well as the accuracy of
the list of funders provided by these databases as compared to a sample of manually collected
1 Giles and Councill (2004) developed an algorithm to extract acknowledgements (and funding data included
in these) of about 335,000 research documents within the CiteSeer computer science archive. This algorithm
searched for lines of text that included acknowledgement information achieving a level recall of about 90% —
i.e. about 10% of acknowledgment data were not retrieved.
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funding data on UK cancer research. Finally, we provide further elaboration on the value of
carefully gathered funding data for profiling funders’ portfolios and national funding landscapes.
3 Data and methods
Our empirical analysis is focused on the UK cancer research domain, which is particularly
suitable for the purpose of this paper for two main reasons. First, cancer research has been
characterised by intense funding activity over the last few decades. This has involved a large
variety of funders — from industry to government and philanthropic organisations (Eckhouse
et al., 2008). Second, cancer research falls within the broader domain of biomedical research
where the rates of reporting funding data in the acknowledgement sections of publications are
relatively high (Dawson et al., 1998).
The search set out to capture all publications in the domain of cancer research, involving at
least one author from a UK research host organisation, and published in the year 2011. Delin-
eating a broad topic such as cancer is, however, a complex task from a bibliometric perspective
due to the breadth of the ‘cancer’ field. We therefore preferred to rely on the Medical Subject
Heading (MeSH) classification of MEDLINE/PubMed, an extensively developed and evolving
vocabulary of medical terms (Leydesdorff et al., 2012; Petersen et al., 2016). The MeSH clas-
sification is composed of several thousands of descriptor terms, representing topics in medical
research — 26,404 descriptors composed the 2011 MeSH classification. These descriptors are
organised in a tree-like structure and assigned, through a standardised indexing process per-
formed by examiners at the US National Library of Medicine (NLM), to MEDLINE/PubMed
publications in order to classify the content of these at different levels of specificity.2
We defined cancer research using the MESH descriptor “Neoplasms” (which captures any
of its children descriptors, such as different types of cancer). The “Neoplasms” descriptor is
formally defined as: “New abnormal growth of tissue. Malignant neoplasms show a greater degree
of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms”.
We queried MEDLINE/PubMed for 2011 data in early 2013, by using the following search string:
2 A descriptor may belong to more than one branch of the MeSH tree and may be complemented by qualifiers
that further specify a publication’s content in relation to the assigned descriptor. For more details on the
classification see www.nlm.nih.gov/pubs/factsheets/mesh.html.
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Figure 1: Journal-publication distribution (a) and top-10 most frequent journals (b).
Source: Authors’ elaboration.
“Neoplasms”[MeSH Terms].3 This returned 115,101 documents published globally in that year.4
MEDLINE/PubMed data were matched with SCOPUS data to retrieve bibliographic data
on all authors’ affiliation addresses as MEDLINE/PubMed provides affiliation data only for the
first listed author in the given publication. Records between the two databases were matched
on the basis of the “PubMed unique identifier” (PMID) field of MEDLINE/PubMed that is also
included in SCOPUS records. SCOPUS-MEDLINE/PubMed match was, however, obtained for
98.1% of the records. The full match was not achieved because of time lag in publication indexing
between MEDLINE/PubMed and SCOPUS (even though data collection began in early 2013, a
full year after the close of the target year).
This match enabled us to identify UK publications as those involving at least one author
based in a UK research host organisation — unmatched records were manually screened. We
sought to include as many records as possible — including all publication types (from editorials
to reviews and all forms of research papers).
This process returned 7,922 publications, indicating that UK authors are represented in
3 Retrieving publications related to cancer by using the MeSH descriptor “Neoplasms” inevitably misses some
of those publications that might be deemed by researchers or funders to be associated with ‘neoplasms’. For
example, a funder or researcher may consider studies of angiogenesis in healthy tissue to be relevant for un-
derstanding how tumours develop a blood supply, but if these papers are not considered to actually study
cancerous tissue they may not be understood as within the study of neoplasms per se, and they will not be
coded using the “Neoplasms” descriptor (or its children descriptors). The publications collected by the search
employed in this study are therefore referred to as a ‘sample’, reflecting the fact that the search is exhaustive
within the neoplasms field (including cancerous and pre-cancerous growths, but also non-cancerous growths,
which we accept as a minor limitation), but not comprehensive of neoplasms by other definitions.
4 We used the electronic date, i.e. the earliest date when a document is made publicly available.
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6.9% of the global production of publications on cancer for 2011. Publications were distributed
across 1,449 journals. As depicted in Figure 1a, the journal-publication distribution is skewed
— the British Journal of Cancer is the journal in which UK publications on cancer were most
frequently published in 2011 (see Figure 1b). We were not able to electronically access 130
journals (712 records) due to access restrictions. E-mails to authors provided access for about
about 42% of publications included in these journals. As a result, we obtained access to the
full-text of 7,510 publications (94.8% of the initial sample of publications). For each of these,
we collected and coded acknowledgements to funders that authors made, as detailed below.
4 Extracting funding data
The automatic extraction of funding information from acknowledgment sections in publications
is challenging. As discussed above, authors use acknowledgments for a variety of purposes.
Our focus is on financial support (e.g. external grants) that authors have received in order to
undertake research that is then reported in a given publication. Funding data must therefore
be separated from the text reporting other non-financial forms of support. For this reason, for
each publication in our sample, we read the text of acknowledgments (including other sections
that may report funding data), interpreted it, and extracted funding data manually. These
data constitute the ‘reference data’ on which we will assess the recall and precision of funding
data provided by MEDLINE/PubMed and WoS. This section sets out steps taken to assure
consistency in the data collection process, including the heuristics that were used to guide
the coding of sample data (together with illustrative examples). These heuristics may be of
assistance for future studies adopting similar approaches or aimed at developing routines capable
of extracting funding information from acknowledgements in an automatic manner.
The first step of data collection was the identification of the portions of publication full-text
where funding data are reported. These data, as expected, are often included in the acknowl-
edgment sections, which are usually positioned before or after references, or, in a few cases, at
the beginning or in the footnotes of the publication. However, there are cases where funding
information is reported in dedicated sections called, for example, “Financial Support”, “Finan-
cial Information”, or “Funding”. These are often located next to the acknowledgment sections.
Case 1 in Table 2, for example, presented two separate sub-sections: “Acknowledgements” and
“Funding”. There are also cases of publications where funding information is reported in mul-
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Table 2: Cases of acknowledgment text and reporting of funding data (extracted funding information is
represented with bold font).
Case Acknowledgement text
1 Acknowledgements
The authors thank our colleagues who have suggested or contributed data for current or previous
versions of the database. They also would like to thank the swift and helpful advice from the ICGC
DCC and BioMart team.
Funding
Cancer Research UK (programme grant C355/A6253) and FW6 EU project MolDiag-Paca.
R.C. is funded by Breast Cancer Campaign. Funding for open access charge: Cancer Research
UK.
(Cutts et al., 2011)
2 Acknowledgments
We are grateful to Ms. Haruka Sawada and Ms. Noriko Ikawa for technical assistance. Our
bio-repository is supported by funding from the National Institute for Health Research (UK)
and the Cambridge Biomedical Research Centre. This work was supported by a Grant-in-
Aid for Young Scientists (A) (22681030) from the Japan Society for the Promotion of Science.
Disclosure Statement
The research was funded by OncoTherapy Science, Inc. YI, YY, and KM are employees of
OncoTherapy Science, Inc. YD, YN, and RH are scientific advisors of OncoTherapy Science, Inc.
(Takawa et al., 2011)
3 Funding
Grant Agency of Czech Republic (303/09/0472 and 305/09/H008); Ministry of Education
of Czech Republic (MSM0021620808 and 1M0505). Work at the Institute of Cancer Research is
supported by Cancer Research UK. Portions of this work were funded by National Institutes
of Health (R01 ES014403 and P30 ES006096 to D.W.N. and Z.S.).
Acknowledgments
The authors would like to thank the Grant Agency of the Czech Republic and the Ministry of Edu-
cation of the Czech Republic.
(Stiborova´ et al., 2012)
4 Acknowledgments
The authors wish to thank colleagues in the Histology Laboratory and the Electron Microscopy Unit,
Veterinary Laboratory Services, School of Veterinary Science, University of Liverpool, for excellent
technical support. T. Soare was supported by a scholarship from the Agency for Credits and Studies,
Romanian Ministry of Education, Research and Innovation.
(Soare et al., 2012)
5 Acknowledgments
MG was supported by the grant Gu 1170/1-1 of the German Research Foundation. The support
for using the research version of the Pinnacle treatment planning software from Philips Radiation
Oncology Systems, Fitchburg, WI, USA is acknowledged. This work was partially supported by re-
search Grant C46/A2131 from Cancer Research UK. We acknowledge NIHR funding to the NHS
Biomedical Research Centre. The fruitful discussions and thoughtful proofreading of the manuscript
by Kevin Brown and Joel Goldwein (Elekta) is acknowledged.
(Guckenberger et al., 2011)
6 Acknowledgments
The study was supported by the grant MA1659/6-1/2 of the Deutsche Forschungsgemeinschaft
(DFG). The recombinant topoisomerase II was a generous gift of Fritz Boege, Institute of Clinical
Chemistry and Laboratory Diagnostics, Heinrich Heine University (Duesseldorf, Germany). We
thank Dr. Antonella Riva and Dr. Paolo Morazzoni (Indena SpA, Milan, Italy) for provision of
test material. The authors have declared no conflict of interest.
(Esselen et al., 2011)
Notes: Publications for cases 3 and 4 were electronically published in 2011, but included in a journal
volume and issue in 2012.
Source: Authors’ elaboration.
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tiple sections. For example, in Case 2, the analysis of the acknowledgments section only would
have inevitably missed funding to this publication coming from the industry, as accounted for
in the disclosure of conflict section.
Case 2 also provides indication of the importance of interpreting the wording used by authors
to declare financial support. For example, it is crucial to distinguish between past and current
financial support made available to the authors (e.g. historic honoraria as opposed to direct
funding for research leading to a given publication). In addition, Case 2 reveals that the authors
acknowledged their employer as funding the study. However, in many cases authors do not do
so, and where they do not, it is important to note that we do not infer that their employer
was the funder of the research. We have only extracted funding information that is explicitly
declared by authors.5
Once the relevant funding information for a given publication is identified, the information
included in this section requires interpretation before being coded, i.e. before the list of funders
can be defined. In certain cases, identifying the list of organisations that financially supported
a publication is relatively straightforward. There are, however, instances where this distinction
is ambiguous because of the general usage of the term ‘support’ in the English language. As
discussed, authors often use this term to give credits to a variety of types of support such as
financial, material, or moral (e.g. Cronin, 1991). For this reasons, we included an organisation in
the list of funders if we could infer, with a certain degree of confidence, from the acknowledgment
text that the ‘support’ from a given acknowledged organisation was financial. For example, in the
Case 3, we interpreted that “supported by Cancer Research UK” referred to financial support
because this funder was acknowledged in a dedicated funding section. In those cases where
there was no clear way to detect the financial nature of the support acknowledged, we adopted
a conservative approach and assumed that the support was not financial — the acknowledged
organisation was therefore not included in the list of funders.6
5 Previous studies on the use of funding data reported in publication acknowledgments have adopted two different
coding approaches. 8 of the 30 studies listed in Table 1 (notably those by Lewison and colleagues) have
complemented the information on funding reported by authors in acknowledgments with the information on
authors’ affiliations (e.g. when an author of a given publication was found to be affiliated to a firm, the firm
was included in the list of funders of the publication). The remaining studies in Table 1 (22 out of 30) have
instead exclusively focused on the funding information included in the acknowledgments. Our study adopts the
latter approach. This, in turn, enables us to make a broader comparison with the results of previous studies as
well as to conduct a more precise comparative analysis on recalland precision of WoS data, which are based on
the text of publication acknowledgments only.
6 ‘Travel support’, ‘in-kind donations’ and some sorts of support (technical, lab access, access to journals and the
like) are often acknowledged by authors. To choose what constitute acknowledgment for funding and what does
not, we follow our principle to codify as funding support only when we conclude there is a direct link between
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After identifying the relevant funding information, the last step was to codify this information
in a consistent manner. To do so, we first extracted the full name of an organisation as stated in
the acknowledgment text and added the ISO 2-digit code of the country where the organisation is
located as we could infer from the acknowledgment text or authors’ addresses. Funders that were
acknowledged more than once in the same publication were counted only once. Harmonisation
of names was undertaken using the highest organisation level of a funder in most cases. For
example, in Case 4, the highest organisational level is the ministerial level, i.e. Ministry of
Education, Research and Innovation (RO).
The language in which the name of the funder is reported can also be an issue. A funder
based in a non-English speaking country can have its name reported in the acknowledgement
either in the native language (so expressed in a language other than English) or in its translated
English form. The acknowledgments of Case 5 and 6 in Table 2 are a clear example of this,
given that the German Research Foundation and the Deutsche Forschungsgemeinschaft are the
same organisation.
Finally, also the task of adding next to each funder name the ISO 2-digit code of the country
where it is located was not unambiguous. A funder’s country of origin is not always clearly
identifiable by its name or via a web search. In ambiguous cases, we assumed that the organisa-
tion acknowledged was from the same country as the author who acknowledged it if no further
information was available. In case of multinational companies, we used the location of their
headquarters as the home country.
Using the above heuristics helps to ensure consistency in the data collection and codification,
but some degree of ambiguity persists, especially in cases where the wording of the acknowledg-
ment was not clear. Consistent coding was ensured through use of a protocol containing illus-
trative examples (as above) and overseeing the coding process through periodic cross-checking
of entries among the coding team.
5 Results
The sections below report our findings in relation to the extent to which authors acknowl-
edge their funders in the field of cancer research, and on the precision and recall of MED-
the publication and monetary support. So of the three items mentioned, only travel support has to be codified,
given some money were given to pay for travel during the course of the research.
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LINE/PubMed and WoS in retrieving UK cancer publications that report funding information
in their acknowledgments. We also examine the accuracy of the list of funders (acknowledged in
publications) as provided by these databases. We then use the collected data to explore the UK
cancer research funding system and to provide examples of the strategic intelligence that such
data can provide to analysts and policy makers.
5.1 Do UK authors of cancer research acknowledge their funders?
The analysis revealed that 52.1% (3,914 out 7,510 publications) of the sample disclosed at
least one funder.7 We further examined our sample of publications below to explore whether
authors might not be reporting funding information. We first distinguished publications in our
sample in three sub-samples: (i) publications with funding data in acknowledgments (52.1%),
(ii) publications with no funding data in acknowledgments (30.4%), and (iii) publications with
no acknowledgement sections (17.4%).
Publications in each of these sub-samples were then classified by type on the basis of the
classification of publication records provided by SCOPUS, i.e. articles, reviews, conference pa-
pers, editorials, errata, notes, letters, and short surveys. The results of this analysis, which are
depicted in Figure 2, provide evidence that the sub-samples of publications with no acknowl-
edgment sections and with acknowledgements but no named funders are composed to a much
greater extent of ‘less cost-intensive’ publications (conference papers, editorials, errata, notes,
letters, and short surveys) than within the sub-sample of publications with acknowledgements,
i.e. 45.5% and 36.7% against 16.8%. These findings are also in line with previous research (e.g.
Salager-Meyer et al., 2009). Also, about 22% of the publications with no acknowledgment to fun-
ders are represented by ‘less cost-intensive’ research outputs, while this proportion significantly
reduces — it ranges from 0% to 5% — when considering publications with acknowledgment to
at least one funder (see Figure 3).
We then explored two additional explanations for the lack of named funders in publication
acknowledgments: (i) the publication required research funding, but relevant information was
omitted from the publication full-text either by the authors or the publisher; or (ii) the pub-
lication was supported by the authors’ employers, which are indirectly acknowledged through
the authors’ affiliations. To determine how these works were funded, we examined the two sub-
7 The percentage of publications reporting funding data increases to 57.0% (3,741 out 6,560 publications) when
considering only articles and reviews as classified by SCOPUS.
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Figure 2: Reporting of funding data by type of publication.
Source: Authors’ elaboration of the basis of MEDLINE/PubMed and SCOPUS data.
samples of publications with no funding data as follows. First, we randomly selected more than
10% (208) of the publications within the sub-sample of publications with no acknowledgment
sections. A closer examination of this sub-sample revealed that about 38% (79/208) of publica-
tions could be classified as case reports. These are likely to require no external funding other
than the support of authors’ employers. We therefore did not further examine this category of
outputs. For the remaining publications (129/208) an e-mail query was sent to the corresponding
authors. We obtained a response rate of about 38% (49 replies). In about 18% of responses, a
funding contribution to the publication other than the authors’ employers was revealed. In 61%
of responses, authors instead revealed a contribution by their employer, while in the remain-
ing 21% of the cases, authors indicated that the publications did not require any funding. In
summary, we can estimate that 11.2% (0.18*0.62) of the publications with no acknowledgment
sections were actually supported by an external funder, i.e. less than 2% (0.11*1310/7510) of
the entire sample of publications.
We then performed a similar analysis for the sub-sample of publications with acknowledge-
ments but no stated funders. 69% of these publications explicitly stated that they did not
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Figure 3: Number of acknowledged funders by type of publication (“Other outputs” include: books,
conference papers, editorials, errata, letters, notes, short surveys).
Source: Authors’ elaboration of the basis of MEDLINE/PubMed and SCOPUS data.
benefit from financial support. Of the remaining 31% of publications, we randomly selected a
sub-sample of more than 10% (89) publications for further investigation. On reading the papers
we found that about 16% (14/89) of the publications could be deemed to be case reports and
therefore it was assumed no funding (beyond the authors’ employers) was necessary to produce
the publication. Financial support for the remaining publications (75) was queried via e-mail to
the corresponding author, and a response rate of 37% (28 responses) was obtained. About 14% of
responders revealed contribution by funders other than authors’ employers; 50% of the responses
suggested that the research was supported by their employers; authors indicated the remaining
publications did not require any funding. We can therefore estimate that 3.6% (0.31*0.84*0.14)
of the publications with acknowledgements but no stated funders were externally funded, i.e.
about 1% (0.04*2286/7510) of the entire sample of publications.
On the basis of the findings above, we concluded that when a UK cancer publication reports
no funding data, it is likely that the publication was ‘less cost-intensive’ (e.g. editorials, notes,
letters, case reports) and therefore did not require any additional funding or that the publication
was supported by authors’ employers. From a review of the text of acknowledgements and survey
of a sample of the authors, it seems that the omission of all funding information is unlikely — we
estimate overall less than 3% of the entire sample. However, it is clear that sometimes authors
do not think it is relevant to acknowledge their employers for funding the publication — the
disclosure of their address somewhat fulfils this purpose.
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5.2 Precision and recall of MEDLINE/PubMed and WoS
To enable the comparison of the funding data extracted through the process described above
with those available from MEDLINE/PubMed and WoS, we first harmonised the names of the
funders listed in the acknowledgements of the publications included in our sample.8 This led
to the identification of 2,549 distinct funding organisations of which 663 organisations in the
public or charitable sector were based in the UK. A further 1,579 public or charitable sector
organisations were identified outside the UK. Industry (e.g. pharmaceutical companies) were
classified separately, with 307 firms being identified. About 64% of the publications reporting
funding information recognised support from two or more funders, with authors of cancer re-
search publications acknowledging an average of 3.3 funders per publication. We compared these
data, namely the ‘reference data’, with those available in MEDLINE/PubMed and WoS across
few descriptive indicators and in terms of precision and recall.9 This comparison is reported in
Table 3.
MEDLINE/PubMed reported funding information only for 23% of publications (1,712 records).
These publications overlapped with those in the ‘reference data’ in about 96% of the case (1,639
records), while the remaining 4% (73 records) reported funding data even though we could not
identify funding sources in the publications’ full-text (false positives). In other words, MED-
LINE/PubMed did not report funding data for 2,275 publications (false negatives). Accordingly,
MEDLINE/PubMed funding data have very low recall, i.e. 41.9% (1639/(1639+2275)) and rel-
atively high precision of 95.7% (1639/(1639+73)). Yet, MEDLINE/PubMed publications with
funding data identified only 17 distinct funders and 1.4 funders per publication against the 2,549
funders and the 3.3 funders per publication reported in the ‘reference data’. This reflects the fo-
cus of MEDLINE/PubMed on major US funders and few large non-US funding organisations.10
As a result, funders are not correctly listed in 75.2% of the 1,639 true positives. About 73% of
these cases miss at least one funder, while less than 2% of them report at least one funder not
acknowledged in publications’ full-text.
8 The Vantage Point software package aided the harmonisation of organisation names
9 For the sake of clarity, we defined recall as the ratio between true positives (i.e. the number of publications for
which both MEDLINE/PubMed or WoS and the ‘reference data’ reported at least one funder) and the sum
of true positives and false negatives (i.e. the number of publications for which these databases did not report
funding data, but we found funding information in publications’ full-text). Precision was instead defined as the
ratio between true positives and the sum of true positives and false positives (i.e. the number of publications
for which MEDLINE/PubMed or WoS reported funding data, but our analysis revealed no funding information
in publications’ full-text).
10See www.nlm.nih.gov/bsd/grant_acronym.html
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Table 3: Recall and precision of MEDLINE/PubMed and WoS funding data.
Database
Reference data MEDLINE/PubMed ISI Wed of Science (WoS)
Number of publications 7,510 7,510 7,082
Publications reporting 3,914 1,712 3,736
funding data (52.1%) (22.8%) (52.7%)
Recall - 41.9% 92.8%
Precision - 95.7% 94.3%
Before After
harmonization harmonization
Number of distinct 2,549 17 6,714 3,541
funders
Number of funders
per publication
Mean 3.3 1.4 4.1 3.7
Std. Dev. (5.0) (0.8) (6.1) (5.3)
Max 78 6 92 76
Accuracy of the list - 24.8% - 68.0%
of funders
Source: Authors’ elaboration.
In the case of WoS, we first matched our data with WoS data.11 7,082 out of 7,510 publica-
tions (about 94.3%) included in the ‘reference data’ were also found in WoS. We then harmonised
funders’ names listed in the “FU” field of WoS data in order to make WoS data comparable
with the ‘reference data’. The proportion of publications reporting funding data is 52.7% (3,736
records), i.e. similar in proportion to the ‘reference data’. 3,524 publications of these are also
included in the ‘reference data’ (true positives), while WoS did not report funding data for 274
publications for which the ‘reference data’ included funding information (false negatives). 212
publications with no funding information in the ‘reference data’ were instead found to contain
funding data in WoS (false positives). This indicates that within the UK cancer research domain
WoS data recall is of 92.8% (3524/(3524+274)) and its precision is 94.3% (3524/(3524+212)).
These findings also suggest that the recall and precision of WoS funding data vary across re-
search domains — Koier and Horlings (2014) found that WoS did not correctly recognise and
retrieve acknowledgement sections in about 24% of cases of research publications sponsored by
the “Dutch climate programmes” in the field of climate change research.
The number of distinct funders listed in WoS data (after the harmonisation of their names)
11The matching was performed by using the medlineR routine Rotolo and Leydesdorff (2015).
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is much higher than those identified in the ‘reference data’: 3,541 against 2,549. This is also
evident from the average number of funders per publications, i.e. 3.7 in WoS data and 3.3
in the ‘reference data’. To further investigate these differences, we focused on the sample of
publications for which both the ‘reference data’ and WoS reported funding information, i.e.
3,524 publications. Within this sample, WoS did not report the same number of funders as
in the ‘reference data’ in 32.0% of the cases: in 10.5% of the records WoS missed at least one
funder, while at least one funder more than in the ‘reference data’ was included by WoS in
21.5% of the sample. This includes cases where organisations were acknowledged, but under the
guidance provided here (in Section 4) would not be classified as providing financial support. For
example, the acknowledgments of a publication in the sample stated:
“[...] This study was not funded. GPRD operates within the MHRA. GPRD has received
funding from the MHRA, Wellcome Trust, Medical Research Council, NIHR Health Technology
Assessment programme, Innovative Medicine Initiative, UK Department of Health, Technol-
ogy Strategy Board, Seventh Framework Programme EU, various universities, contract research
organisations and pharmaceutical companies. The Department of Pharmacoepidemiology and
Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, has received unrestricted fund-
ing for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-
public funded Top Institute Pharma (www. tipharma.nl, includes co-funding from universities,
government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of
Health [...]” (van Staa et al., 2012).12
Despite the authors? explicit declaration that the focal study did not receive any external
funding, WoS data listed all the organisations, subsequently mentioned in the acknowledgments,
as funders of the publication. This suggests that the “FU” field of WoS requires careful cleaning
to remove cases where organisations are reported as funders despite the clear indication that
they are listed as a declaration of potential conflict of interests (e.g. in the case of authors paid
by companies for unrelated work) and for previous funding, rather than funding of the work
contained in that particular paper.
In summary, the comparison provides evidence that in a very substantial number of cases,
manual coding of the data reveals a different outcome to that provided by MEDLINE/ PubMed
12The publication was electronically published in 2011.
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and WoS.
5.3 Exploring UK cancer funding
This section demonstrates how carefully gathered funding acknowledgements data, although
labour intensive to prepare, can be used to provide research portfolio profiles for individual
organisations as well as providing landscape overviews of wider funding environments. This is
an important approach because alternatives based on self-reporting of funding inputs by re-
search funders have a number of limitations including, inter alia, reliance on funders to provide
data and different data collection and coding conventions amongst funders (Hopkins and Siepel,
2013). Although efforts are underway to bring together and classify funding inputs data (e.g.
the UK Clinical Research Collaboration’s coverage of 60 funders’ self-reporting of funding allo-
cations — mentioned in the introduction) as the data explored in this section show, biomedical
research funding involves a very large number of national and international funders, including
governments, charities and firms, and funding landscape methodologies need to be able to take
this diversity into account.
5.3.1 The contribution of different types of funders
An advantage of collecting funding data from publications is the breadth of funders that it is
possible to reveal without a priori knowledge of the field or privileged access to funders’ data. As
noted above, 2,549 funders were associated with at least one publication by a UK author in 2011,
although, as reported in Figure 4a, the distribution funder-publication is highly skewed. 75%
(1,921) of funders were associated with just a single publication in the sample. More than 296
public and charitable sector funders supported two or more publications. If we define ‘major UK
funders’ as those acknowledged in at least 2% of the publications acknowledging funding in our
sample, these supported about 50% (1978/3914) of the publications. A further 37% (1440/3914)
of publications acknowledging funding were supported by ‘minor UK funders’ (that is, funders
that supported less than 2% of funded publications individually). About 22% (849/3914) of the
sample acknowledged at least one major and one minor UK funder. Although clearly a relatively
small number of funders fund the majority of UK cancer research, these descriptive statistics
highlight the important role that the myriad of small funders play in the overall funding system.
Figure 4 reports the top-10 most acknowledged funders in the categories of UK public sec-
tor and charitable funders (Figure 4b), industry (Figure 4c), and non-UK public sector and
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Figure 4: Funder-publication distribution (a) and top-10 UK (b), industry (c) and non-UK (d) acknowl-
edged funders.
Source: Authors’ elaboration.
charitable funders (Figure 4d). The analysis suggests that international funders make a strong
contribution to UK scientific output. The US National Institutes of Health (NIH) was, for
example, acknowledged in 11.5% of publications in the sample, i.e. in a similar proportion of
publications that acknowledged UK Medical Research Council (MRC). The nature of this contri-
bution is, however, more likely to be via support to the foreign collaborators of UK authors than
to UK authors directly — with unstructured acknowledgements it is impossible to tell which
authors are supported by which funders most of the time. The European Commission (EC)
funding (acknowledged in 9.8% of publications in the sample) is more likely to be provided as
direct support to UK researchers, but much of this will also be linked to international collabora-
tors. Nonetheless, given that 43% of the sample of 7,510 publications involved an international
collaboration, it is clear that the UK cancer research output is substantially supported by fund-
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ing coming from countries like the US, Italy, Sweden and France (and the relationship goes both
ways, clearly). Specifically, about 47% (1853/3914) of the publications acknowledging funders
mention at least a non-UK public sector or charitable funder. Of the 307 firms acknowledged
for their funding in UK cancer publications, large pharmaceutical companies are the industrial
actors most acknowledged in publications, led by Pfizer, AstraZeneca, and Novartis. Collectively
these firms supported about 18% (699/3914) of the publications acknowledging funders. About
20% (141 publications) of these acknowledged at least two industrial actors for funding, thus
providing some indication on the extent to which firms jointly support pre-competitive research.
Funding acknowledgements also enable the exploration of the extent to which funders are
jointly acknowledged in publications (co-funding). Use of the term co-funding for publications
does not imply funders were aware of collaborative work ex-ante. Rather, it is anticipated that
funded researchers work together in ad-hoc combinations in order to drive their research forward.
In some cases, co-funding will be as a result of individual researchers accessing multiple sources
of funding in order to undertake their work. However, again, due to the unstructured nature
of funding acknowledgments it is often difficult to tell how particular funders contributed to a
given publication. Given that our data are focused on the UK context, we only examined the
co-occurrence of UK funders in funding acknowledgements.
Results are depicted in Figure 5, where each node is a UK funder and the width of the tie
between two nodes indicates the extent to which the two funders are jointly acknowledged in
publications. For the sake of clarity in the visualisation, we reported UK funders that were
acknowledged in at least two publications in our sample (296 funders). The analysis revealed
that the UK funders most frequently jointly acknowledged in cancer research publications are
the MRC, Cancer Research UK, and the UK Departments of Health (including the NHS in
England and the devolved regions and NIHR). The majority of funders shown in Figure 5 are
external to the research host organisation undertaking the research. Nonetheless, it is worth
noting that a small proportion of funders are research host organisations that also appear to
support cancer research through internal funds.13 Table 4 also reports the co-occurrence matrix
for the top-10 UK funders.
13Although some authors did acknowledge such contributions, generally, as discussed, authors did not acknowledge
their employers as a funder. However, it is not possible to exclude these where they do occur.
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Figure 5: Co-occurrence of UK funders in publication acknowledgement sections: nodes represent UK
funding organisations (296) acknowledged in at least in two publications (the size of a node is proportional
to the number of publications that acknowledged the funder the node represents, while the width of a tie
is proportional to the number of times the two funders connected by the tie were jointly acknowledged in
publications). The high-definition version of this figure is available at https://dx.doi.org/10.6084/
m9.figshare.2064897.v1.
Source: Authors’ elaboration.
Table 4: Co-occurrence matrix (joint acknowledgements) of the top-10 UK funders.
UK funder 1 2 3 4 5 6 7 8 9 10
1. Cancer Research UK -
2. Departments of Health (NHS, NIHR) 315 -
3. Medical Research Council 216 183 -
4. Wellcome Trust 83 75 86 -
5. Leukaemia and Lymphoma Research 42 24 41 9 -
6. Breakthrough Breast Cancer 51 52 15 10 3 -
7. Breast Cancer Campaign 54 19 7 3 0 7 -
8. Engineering and Physical Science Research Council 44 46 43 7 2 4 2 -
9. Biotechnology and Biology Sciences Research Council 21 10 25 15 9 1 1 15 -
10. Yorkshire Cancer Research 19 14 8 1 3 4 9 0 5 -
Source: Authors’ elaboration.
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5.3.2 Funders’ research portfolios
The MeSH classification enables us to link funders acknowledged in publications and the content
of publications in terms of medical topics. We focused on the third level of the MeSH classifi-
cation and specifically on the ‘children’ of “Neoplasms by Site” and “Neoplasms by Histologic
Type” descriptors, which hold 68% and 43% of the publications in our sample, respectively.
Overall, these descriptors classify 6,174 publications (82.2%).14 The selected descriptors with
the associated number of publications in our sample are reported in Table 5. The three areas
with most publications are glandular and epithelial, digestive system, and urogenital neoplasms.
Table 5: Cancer research areas.
Descriptor Abbreviation Tree number Number of
publications
Neoplasms by Site - C04.588 5,137
Digestive System Neoplasms Digestive System C04.588.274 1,253
Urogenital Neoplasms Urogenital C04.588.945 1,017
Breast Neoplasms Breast C04.588.180 1,008
Head and Neck Neoplasms Head & Neck C04.588.443 663
Endocrine Gland Neoplasms Endocrine Gland C04.588.322 565
Thoracic Neoplasms Thoracic C04.588.894 533
Nervous System Neoplasms Nervous System C04.588.614 373
Skin Neoplasms Skin C04.588.805 287
Bone Neoplasms Bone C04.588.149 236
Soft Tissue Neoplasms Soft Tissue C04.588.839 62
Eye Neoplasms Eye C04.588.364 61
Hematologic Neoplasms Hematologic C04.588.448 60
Abdominal Neoplasms Abdominal C04.588.33 46
Mammary Neoplasms, Animal Mammary (Animal) C04.588.531 23
Pelvic Neoplasms Pelvic C04.588.699 13
Splenic Neoplasms Splenic C04.588.842 5
Anal Gland Neoplasms Anal Gland C04.588.83 1
Neoplasms by Histologic Type - C04.557 3,252
Neoplasms, Glandular and Epithelial Glandular & Epithelial C04.557.470 1,633
Neoplasms, Germ Cell and Embryonal Germ Cell & Embryonal C04.557.465 652
Neoplasms, Nerve Tissue Nerve Tissue C04.557.580 614
Leukemia Leukemia C04.557.337 435
Neoplasms, Connective and Soft Tissue Connective & Soft Tissue C04.557.450 328
Lymphoma Lymphoma C04.557.386 302
Nevi and Melanomas Nevi & Melanomas C04.557.665 229
Neoplasms, Plasma Cell Plasma Cell C04.557.595 132
Neoplasms, Vascular Tissue Vascular Tissue C04.557.645 115
Neoplasms, Complex and Mixed Complex & Mixed C04.557.435 62
Neoplasms, Gonadal Tissue Gonadal Tissue C04.557.475 11
Lymphatic Vessel Tumors Lymphatic Vessel Tumors C04.557.375 10
Histiocytic Disorders, Malignant Histiocytic Disorders, Malignant C04.557.227 5
Odontogenic Tumors Odontogenic Tumors C04.557.695 1
Source: Authors’ elaboration on the basis of MEDLINE/PubMed data.
14The publication count includes also descriptors at lower levels of the MeSH classification. 1,126 publications
(15%) are classified as “Neoplasms” at the first level of the MeSH tree, i.e. no additional MeSH descriptors at
second or lower levels are reported. Other second-level descriptors under the “Neoplasms” are assigned to 934
publications.
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We used this classification to profile cancer research supported by four UK funders: Can-
cer Research UK, the Medical Research Council (MRC), the Engineering and Physical Sci-
ence Research Council (EPSRC), and the Biotechnology and Biology Sciences Research Council
(BBRSC) — a broader set of cases is available elsewhere (Shah et al., 2014). These funders
were acknowledged in 24.2%, 12.2%, 2.4%, and 2.3% of the sub-sample of publications reporting
funding data, respectively — the low percentage for the last two cases is expected given that
cancer research is not the main focus of these funders (indeed their strategic priorities extend
beyond healthcare). Figures 6 and 7 profiles the four funders in terms of the proportion of re-
search that they supported in a given cancer domain, relative to overall number of publications
that they supported in cancer.
Figure 6a shows that Cancer Research UK’s support is mostly focused on breast, digestive
system, glandular and epithelial, and urogenital areas. A similar profile can be observed for
the case of MRC (Figure 6b) except for breast neoplasm, where CR-UK has a much more
pronounced focus in its portfolio than MRC. EPSRC (Figure 7a) has also a similar portfolio in
its cancer-related funded research (despite cancer not being the main focus of this funder). In
the case of BBSRC (Figure 7b), the analysis shows that this funder tends to support research
on germ cell and embryonal, thoracic, and nerve tissue neoplasms as well as on leukaemia and
lymphoma. It is worth noting that about 15% of the BBSRC-funded publications are within the
thoracic neoplasm area, while less than 10% of the publications supported by Cancer Research
UK, EPSRC, and MRC fall within this area. Thoracic neoplasms include lung neoplasms, which
account for the biggest cancer burden (Stewart and Wild, 2014).
6 Discussion and conclusions
At the present time there is an increasing pressure on research funding. At the same time,
there is increasing access to data, facilitated by the Internet and improvements in computing
power. These trends have combined to give new impetus for the use of funding data to analyse
relationships between funding inputs and research outputs, such as publications. Funders have
started to invest in large data infrastructures. For example, the US NIH’s grants have been
linked to their outcomes (publications and patents) in the RePORTER database, which is also
made publicly available. Similarly, an increasing number of UK and international funders are
relying on Researchfish to capture outcomes generated from their funded research, while the
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Figure 6: Profile of four UK funders’ research portfolios by cancer types (as based on the ‘abbreviated’
MeSH descriptors assigned to publications): Cancer Research UK (a) and MRC (b).
Source: Authors’ elaboration.
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Figure 7: Profile of four UK funders’ research portfolios by cancer types (as based on the ‘abbreviated’
MeSH descriptors assigned to publications): EPSRC (a) and BBSRC (b).
Source: Authors’ elaboration.
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UK Clinical Research Collaboration has focused on the collection and analysis of data on the
portfolios of scores of charitable and public sector funders. However, these ‘top-down’ initiatives
allow analysis only of research that funders have shared. Many funders that also contribute to
funding systems are excluded. The analysis of funding data included in the acknowledgment
paratext of scientific publications this paper has focused is instead a ‘bottom-up’ approach,
which, in turn, can provide a more comprehensive perspective on the variety of funders involved
in funding systems. This does not rely on a priori knowledge of the population of funders nor
does it require funders’ support to access the data. Nevertheless, significant challenges exist in
the collection process (extraction and coding) of these data.
This paper has addressed a series of questions related to the use of this ‘bottom-up’ approach
to gathering funding data. To do so, we focused on a sample of 7,510 publications published
in 2011 in cancer research by UK authors. First, the paper sets out a number of heuristics for
guiding the collection and coding of funding data included in acknowledgements paratext. These
can inform future studies that aim to build datasets of funding data from publications as well
as to develop natural language algorithms capable of extracting funding information from the
acknowledgements paratext automatically.
Second, we have examined the extent to which authors acknowledge funders in their publica-
tions. We specifically reviewed extant literature on the use funding data. These studies suggest
that the reporting of funding data in publications is relatively limited in certain domains, such
as some social sciences, due to their lower reliance on grant funding than the natural sciences,
in which authors tend to acknowledge external funders more frequently. On the basis of read-
ing and interpreting acknowledgements sections and surveying UK (corresponding) authors of
a sample of publications that did not contain acknowledgements to funders, we estimated that
in less than 3% of the cases funding acknowledgements were entirely omitted when at least one
external funder should have been disclosed.
Third, we provide evidence on the ‘quality’ of funding data available in existing publication
databases. Specifically, we compare MEDLINE/PubMed and ISI Web of Science (WoS), with
those data that we manually collected and extracted following the heuristics we set out. On the
one hand, we found that MEDLINE/PubMed has a very low recall (about 42%), thus many pub-
lications that include funding information are not identified as such by this database. Also, given
the focus of this databases on few funders, those MEDLINE/PubMed records including funding
information correctly listed funders in only about 25% of the cases. On the other hand, WoS
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reported values of recall and precision well above 90%, but the set of funders acknowledged in a
publications were not correctly listed in about 32% of the cases (i.e. the list of funders provided
by the “FU” field could not be reconciled with the authors’ reading of the acknowledgements
paratext).
Fourth, through the application of bibliometric analysis to these data, we illustrated how
funding data can be used to inform policy making on research funding. We used the data
to provide a number of illustrative examples of major (charitable, governmental and private)
funders supporting cancer research in the UK, showing the extent to which funders are co-
funding research publications (i.e. being jointly acknowledged in the same publications), and
profiling the research portfolios of these funders by cancer type.
Implications for development and use of funding data can be derived on the basis of these
findings. Our review of extant literature on the proportion of publications with funding ac-
knowledgements found a lack of studies on similar fields and regions over time. As a result, it
remains difficult to determine whether the propensity to acknowledge funders has increased or
not in recent years — although one could argue that funders’ efforts to link their funding to
outputs and journals’ efforts to boost transparency should yield an improvement, particularly
in the biomedical field.
Funders, journal editors and publishers have an important role to play in ensuring better
reporting and transparency. Standardisation of the reporting modes of funding (e.g. consistent
linking of particular funders to authors) would be a major contribution to the utility of funding
data. It is often not possible to identify how much funding is linked to a given author or even
to identify which author is acknowledging a funder linked to a publication. Also, authors can
strategically (or mistakenly) acknowledge funders that have not supported the specific publi-
cations in which they are mentioned. It is generally not possible to link publications with the
quanta of research funding using funding acknowledgements paratext.
It is desirable that the contributions of all kinds of funders should be recognised. There
is a clear tendency to acknowledge external funders, but not to acknowledge funding support
from authors’ employers and funders that provide block funding (e.g. the UK Higher Education
Funding Council was acknowledged in about 0.4% of the publications included in our sample).
Such omissions are a substantial hindrance to the accurate description of funding landscapes.
Improvements in transparency and completeness of funding data would be to the benefit of
analysts of funding systems, as the potential for comprehensiveness of the bottom-up approach
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are attractive.
The findings reported here also have important implications for future research on funding
data. We provided evidence that the “FU” field (list of funders included in publications’ ac-
knowledgements) of WoS has some major limitations, with around one third of records in our
sample not being correctly coded. These limitations may, however, be less prominent in areas
of science that have lower funding intensity, for example with fewer funders per publication. It
is worth noting that, the “FX” field (including the full-text of publications’ acknowledgements)
provided by WoS can be a helpful starting point to build datasets matching funding sources with
scientific publications. Nonetheless, these data also require substantial cleaning and aggregation
to ensure that all of the publications related to a given funder are appropriately linked. MED-
LINE/PubMed can provide indications of funding activity for only a limited number of major
US and non-US funders and therefore is not a suitable starting point for analysis of funding
landscapes owing to the large number of funders that are not captured in the data at present.
Much of this paper has focused on cautions of the limitations of funding data, and naturally
the analysis provided here suffers from many of the shortcomings we have identified, particularly
in relation to data coverage. Those working with data outside biomedical sciences will likely find
these problems too. Those seeking to provide longitudinal analysis on the dynamics of funding
systems, which we have not explored here, will likely find the difficulties in applying our approach
will multiply. Yet such efforts are worthwhile as bottom-up efforts to study funding systems
have much to offer in terms of strategic intelligence for policy-making (Rotolo et al., 2015).
This includes intelligence on active funders, joint-funding (as in the extent to which funders are
jointly acknowledged in publications), and profiling of funders’ research portfolios (e.g. which
areas are more intensively supported by certain funders and where funders’ interests overlap).
Dynamic data can show how interaction between types of funder may be causally linked to
certain benefits for particular types of research. This can aid the design of funding programmes
and systems as well as improving our understanding of how funders may be complementary or
interdependent.
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